|
Clinical Integration updates: View the latest program update including an on-demand webinar outlining key 2023 program updates and measure changes.
Mandatory education: APP physicians and APCs are required to complete Mandatory Education courses on the Workday Extended Enterprise Learner platform by June 19. There are currently four required courses:
• Compliance and Integrity
• Safety Review
• High Reliability Tools and Tactics
• Safety and Respect: Compliance for Managed Care
Important: In error, APP aligned physicians and APCs were assigned a Sexual Harassment Prevention course. This course is not required and does not meet IDFPR requirements for license renewal. Until the course is removed from your assignment, please disregard. If you require assistance accessing the workday system, please contact the APP Network Management Team at APP-advocatephysicianpartners-EDS@aah.org.
Medicare Advantage open enrollment – now live: Through March 31, patients in a Medicare Advantage (MA) plan have the opportunity to switch to a different MA plan or return to original Medicare. We are in network with Devoted Health in Illinois for MA HMO plans, in addition to other major MA plans. To address patient questions:
Risk plan pharmacy – utilization management coverage update: Updates have been made to the medical benefit coverage for viscosupplement products; a precertification questionnaire is now required during referral entry. Find current EPH precertification questionnaires on APP Pro.
Cryoprecopitate shortage: Currently there is a nation-wide shortage of cryoprecipitate (Cryo). Read SBAR and follow these conservation steps:
- Orders should be placed for one pooled Cryo at a time so that products are appropriately utilized.
- If Cryo is thawed and not used, it is frequently wasted. Please do not order unless you are sure of the clinical need for this blood product.
- For patients that need fibrinogen replacement, and cryoprecipitate is unavailable, Fibryga can be utilized.
Pharmacy & Therapeutics February updates: Review the latest Pharmacy and Therapeutics ambulatory and system committees decisions. View summary.
Elimination of DATA-Waiver Program: The DATA-Waiver program, created to allow physicians and APCs to prescribe medications such as buprenorphine outside of an opioid treatment program, has been eliminated. Here’s what you need to know:
- All physicians and APCs who have a current DEA registration may prescribe buprenorphine for an opioid use disorder (when permitted by applicable state law).
- Limits no longer exist for the number of patients a prescriber may treat for an opioid use disorder.
- A Notice of Intent (NOI) is no longer required to be submitted to the DEA and SAMHSA to obtain an X-Waiver (aka X-DEA or NADEAN).
- Entering the X-DEA or NADEAN into “Notes to Pharmacy” within Epic when prescribing buprenorphine-naloxone products is no longer necessary.
With the elimination of this program, new training will be required when applying for or renewing your DEA registration. This training is effective June 21 and further details regarding training will be provided in the future. Resources:
Transmission-based isolation grid: The transmission-based isolation grid has recently been updated to include the ACL respiratory viral panel, reflective of the CDC and Redbook recommended isolation practices. See the TBI Grid.
Saving lives – blood donation: Register today for a blood drive to ensure an adequate and continuous blood supply throughout our communities. Sign up to donate.
Reminder: Voting for U.S. News Best Hospital: Voting is now open for the 2023-2024 U.S. News & World Report’s Best Hospitals list. This survey counts for about 15% of a hospital’s overall score. See who's eligible and how to vote.
Advancing Research:
| 
